Belsomra 20mg cut CSF amyloid-β by ~20%
In a 2023 human trial, 20 mg of suvorexant (Belsomra) decreased CSF amyloid-beta by roughly 20% starting about 5 hours after administration.
Snapshot · The Peter Attia Drive
#394 ‒ Sleep pharmacology: the role of medications in healthy sleep, the promise of emerging therapies, and the evidence for common sleep supplements
Explore episode
Jun 1, 2026
Where this was said
Dual orexin receptor antagonists (DORAs) and the future of sleep medicine: orexin signaling, sleep architecture, and the emerging connection between sleep and Alzheimer's disease
At 32:40 · chapter starts 27:15
During slow-wave sleep, the brain's glymphatic system activates — neurons shrink slightly, opening about 60% more interstitial space, allowing CSF to circulate freely and carry away metabolic toxins including beta-amyloid and aberrant tau proteins implicated in Alzheimer's disease. Animal studies show glymphatic amyloid clearance roughly doubles during sleep, especially deep slow-wave sleep. Human studies confirm that even a single night of sleep deprivation impairs this clearance, and chronic disruption correlates with long-term amyloid and tau burden. The accumulation of these proteins in turn damages the brain regions that regulate sleep, creating a vicious cycle. Researcher David Holtzman suspected an orexin-amyloid link, since both orexin levels and CSF amyloid follow similar diurnal rhythms. His group infused orexin into mouse hippocampi and found it raised interstitial amyloid; the early DORA almorexant lowered it. Dayvigo in tau-mutant mice slowed tau pathology and brain atrophy in male mice. In a landmark 2023 human trial of 38 adults aged 45–65, 20 mg of Belsomra — but not 10 mg — reduced CSF amyloid-beta by ~20%. Ambien had no such effect. This specificity is critical: simple unconsciousness isn't doing the clearing. Three new clinical trials — two with ~200 subjects each — are underway and expected to report between now and 2029.
DORAs: The First Sleep Drugs That Don't Force Sleep
DORAs work by dialing down the brain's orexin-driven wakefulness system rather than forcing sedation — a fundamentally different mechanism that preserves sleep architecture and even improves REM sleep. Meta-analyses show superior sleep efficiency and tolerability compared to older drug classes.
DORAs and Alzheimer's Prevention: An Exciting Signal
The brain's glymphatic waste-clearance system — which flushes amyloid and tau during deep sleep — roughly doubles its clearance rate during slow-wave sleep. DORAs preserve that architecture, and a 2023 human trial found 20 mg of suvorexant reduced CSF amyloid-beta by about 20%. The data are early but the signal is strong enough to warrant close attention.
Glymphatic space opens ~60% during sleep
During sleep, neurons shrink slightly, opening about 60% more interstitial space, allowing the glymphatic system to flush beta-amyloid and tau proteins from the brain.
Glymphatic amyloid clearance doubles in sleep
Animal studies show glymphatic clearance of beta-amyloid roughly doubles during sleep, particularly during deep non-REM slow-wave sleep.
Melatonin Is a Clock, Not a Sedative
Melatonin doesn't knock you out — it tells your brain what time it is. The optimal dose to shorten sleep latency is just 4 mg, yet most people take 5–10 mg, which can backfire by disrupting circadian alignment. And commercial product accuracy is so poor that actual content can range from 80% below to nearly 500% above the label claim.
Similar snapshots
540M years ago: first animal vision
Animals first sensed light 540 million years ago, triggering an evolutionary acceleration known as the Cambrian explosion within 10 million years.
50% of cortex involved in vision
It is estimated that half of all cortical activity in the human brain is involved in visual function, underscoring vision's central role in intelligence.
Human 6-year-olds learn tens of thousands of object categories
Cognitive neuroscience literature shows that by age 6, humans can recognize tens of thousands of different object categories — far more data than early AI systems were trained on.
~3% of FDA drugs have unclear mechanisms
Only about 3% of FDA-approved drugs have genuinely unclear mechanisms of action, making an unknown mechanism a meaningful early red flag for any compound.
30–50% of phase 1 drugs fail to reach phase 2
Even compounds that clear preclinical testing often fail in humans: 30 to 50% of drugs entering phase 1 trials do not advance to phase 2, frequently because human behavior differs from animal models.
BPC-157 published work: >80% from one group
More than 80% of published BPC-157 research comes from a single academic group whose researchers have IP and commercial interests connected to the molecule, limiting independent replication.
~100 approved peptide drugs; ~150 in trials
Roughly 100 peptide drugs are already FDA-approved, about 150 more are in clinical trials, and 600–700 are in preclinical development, underscoring the legitimacy of peptide science broadly.
BPC-157 founder withheld screening method
The scientist who discovered BPC-157 refused to disclose the screening method used to identify the compound and has never fully published the parent protein sequence — what Peter Attia calls 'scientific trust me, bro.'
Brain barely distinguishes imagined vs real
The brain's visual, auditory, and motor cortices light up nearly identically whether an experience is real or imagined, making visualization a form of actual neural training.
